- Home
- HRTX vs RAPT Comparison
HRTX vs RAPT Comparison
Compare HRTX & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- RAPT
- Stock Information
- Founded
- HRTX 1983
- RAPT 2015
- Country
- HRTX United States
- RAPT United States
- Employees
- HRTX N/A
- RAPT N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- HRTX Health Care
- RAPT Health Care
- Exchange
- HRTX Nasdaq
- RAPT Nasdaq
- Market Cap
- HRTX 206.9M
- RAPT 194.2M
- IPO Year
- HRTX 1987
- RAPT 2019
- Fundamental
- Price
- HRTX $1.21
- RAPT $18.00
- Analyst Decision
- HRTX Strong Buy
- RAPT Buy
- Analyst Count
- HRTX 2
- RAPT 5
- Target Price
- HRTX $4.50
- RAPT $33.60
- AVG Volume (30 Days)
- HRTX 1.4M
- RAPT 89.6K
- Earning Date
- HRTX 11-11-2025
- RAPT 11-11-2025
- Dividend Yield
- HRTX N/A
- RAPT N/A
- EPS Growth
- HRTX N/A
- RAPT N/A
- EPS
- HRTX N/A
- RAPT N/A
- Revenue
- HRTX $149,694,000.00
- RAPT N/A
- Revenue This Year
- HRTX $10.62
- RAPT N/A
- Revenue Next Year
- HRTX $12.99
- RAPT N/A
- P/E Ratio
- HRTX N/A
- RAPT N/A
- Revenue Growth
- HRTX 9.78
- RAPT N/A
- 52 Week Low
- HRTX $1.04
- RAPT $5.67
- 52 Week High
- HRTX $2.68
- RAPT $26.56
- Technical
- Relative Strength Index (RSI)
- HRTX 28.21
- RAPT 81.43
- Support Level
- HRTX $1.25
- RAPT $11.19
- Resistance Level
- HRTX $1.27
- RAPT $13.66
- Average True Range (ATR)
- HRTX 0.06
- RAPT 1.04
- MACD
- HRTX 0.01
- RAPT 0.58
- Stochastic Oscillator
- HRTX 8.70
- RAPT 96.62
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.